A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

@article{Dy2005API,
  title={A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.},
  author={Grace Kho Dy and Laura M. Bruzek and Gary A. Croghan and Sumithra J. Mandrekar and Charles E Erlichman and Prema P. Peethambaram and Henry C. Pitot and Lorelei J. Hanson and Joel M. Reid and Alfred Furth and Shinta Cheng and Robert Martell and Scott H. Kaufmann and Araba A. Adjei},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2005},
  volume={11 5},
  pages={1877-83}
}
PURPOSE This phase I study was conducted to determine the toxicities, pharmacokinetics, and pharmacodynamics of BMS-214662, a farnesyl transferase inhibitor, in combination with paclitaxel and carboplatin, in patients with advanced solid tumors. EXPERIMENTAL DESIGN Patients with solid tumors received one of six escalating dose levels of BMS-214662 infused over 1 hour given following paclitaxel and carboplatin on the first day of a 21-day cycle. Toxicities were graded by the National Cancer… CONTINUE READING